Anti-bone metastasis drugs currently include bisphosphonates and disumab. The principle of bisphosphonates is to inhibit the activity of mature osteoclasts, reduce the bone resorption caused by osteoclast activity and thus inhibit the process of bone metastasis. In addition, bisphosphonates can also promote osteoclast apoptosis. Commonly used drugs include zoledronic acid and ibandronate sodium. Dessutumab is a targeted drug that can block the relevant ligands on the surface of osteoclasts to inhibit osteoclast activation and maturation, and then inhibit osteoclast activity to reduce bone resorption and destruction caused by malignant tumor bone metastasis. Anti-bone metastasis treatment drugs have strict indications and contraindications, need to be used under the guidance of a professional doctor, it is recommended that patients go to the hospital as soon as possible, consult a professional doctor, do not recommend the use of drugs at will to avoid causing adverse reactions.